In the United States, GLP-1 RAs such as liraglutide and semaglutide have been licensed by the US Food and Drug Administration (FDA) for the treatment of obesity and excessive weight, regardless of whether the patient has diabetes. The gene discussed is GLP1R; the disease is obesity disorder.